Day: August 18, 2020

100125-12-0, 3,8-Dibromo-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a three-necked flask of 500 ml, 1.0 g (2.96 mmol) of 3, 8-dibromo-1, 10-phenanthroline [6] [*2),] 2.9 g (11.8 mmol) of fluorantene-8-boronic acid [7], 140 ml of toluene and 70 ml of ethanol were charged and an aqueous solution of 12 g of sodium carbonate/60 ml of water was dropped under stirring at room temperature in a nitrogen atmosphere, and then 0.17 g (0.15 mmol) of tetrakis (triphenylphosphine) palladium (0) was added. After stirring at room temperature for 30 minutes, the mixture was raised to a temperature of [77C] and stirred for 3 hours. After the reaction, the organic layer was extracted with chloroform and dried with anhydrous sodium sulfate, and then purified with an alumina column (hexane/chloroform solvent mixture developer), obtaining 1.4 g (yield of [82%)] of Exemplary Compound No. 8 (yellow crystal).

As the paragraph descriping shows that 100125-12-0 is playing an increasingly important role.

Reference£º
Patent; CANON KABUSHIKI KAISHA; WO2004/26870; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 2-(1,4,7,10-tetraaza-4,7,10-tris{[(tert-butyl)oxycarbonyl]methyl}-cyclododecyl)acetic acid (68.7 mg, 0.120 mmol) in dry DMF (1.00 mL) was successively treated with HOBt (18.4 mg, 0.120 mmol) and EDC (22.9 mg, 0.120 mmol) at 22 C. After 0.5 h, the solution was treated with the product of Part 18A (40.8 mg, 0.100 mmol) and the resulting mixture stirred 0.5 h. The intermediate conjugate thus obtained was once again activated with EDC (22.9 mg, 0.120 mmol), then stirred 0.5 h before final treatment with MeONH2.HCl (10.0 mg, 0.120 mmol). After 1 h, the resulting mixture was diluted with EtOAc (100 mL) then transferred to a separatory funnel and successively washed with 0.1 M NaOH and saturated aqueous NaCl (3¡Á25 mL each). The EtOAc solution was dried over MgSO4, filtered and concentrated in vacuo to a colorless oil, which was used without further purification in the subsequent deprotection step.The protected conjugate (0.120 mmol theoretical) was dissolved in dioxane (1.00 mL) then successively treated with H2O (9 muL) and HCl (4.00 mmol; 1.00 mL of a 4 M solution in dioxane) at 22 C. The resulting pale yellow solution was stirred 14 h, during which time a heavy white precipitate formed. Upon complete deprotection, the volatiles were removed under a stream of N2 and the white solid residue redissolved in H2O containing 0.1% TFA (8.00 mL) then directly purified by HPLC on a Phenomenex Luna C18 column (21.2¡Á250 mm) using a 1%/min gradient from 0-30% MeCN containing 0.1% TFA and 10% H2O at 20 mL/min. The main product peak eluting at 11.5 min was collected and lyophilized to a white powder (12.8 mg, 13.4 mumol; 13.4%).

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Lantheus Medical Imaging, Inc.; Cesati, Richard R.; Harris, Thomas D.; Robinson, Simon P.; Looby, Richard J.; Cheesman, Edward H.; Yalamanchili, Padmaja; Casebier, David S.; (86 pag.)US9266846; (2016); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

330680-46-1, Trimethyl [2,2′:6′,2”-terpyridine]-4,4′,4”-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1.3g of the compound of the d-1-6 with one equivalent ofCompound d-1-7 NMP (N- methyl pyrrolidone) was stirred for 3 hours in the atmosphere of nitrogen at 70 was added to 150ml. Then compound d-1-8 by the addition of 1 eq., Was stirred at 160 time Heating 8, by the addition of 10 eq of ammonium Ansan between arylthio was stirred at 160 8 hours. After concentration of the resulting solution, by addition of water and filtered. Purification of the filtered water to the silica gel column chromatography, and then the obtained compound d-1-9, was added to a mixed solvent of 30ml of acetone and 40ml 1N sodium hydroxide aqueous solution, was stirred for 24 hours at an external temperature of 65 . It returned to room temperature, adjusted to pH 3 with hydrochloric acid and filtered the precipitate to give 2.5g of crude D-1-5a.

The synthetic route of 330680-46-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJI FILM CORPORATION; WATANABE, KOSUKE; SATO, HIROTAKA; TANI, YUKIO; FUJIWARA, RYO; TSUNA, KAZUHIRO; KOBAYASHI, KATSUMI; (82 pag.)KR2015/129778; (2015); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1435-55-8,Hydroquinidine,as a common compound, the synthetic route is as follows.

EXAMPLE 23 Synthesis of Methylphenylcarbamoyl dihydroquinidine (MPC-DHQD) Dihydroquinidine (1.4 g, 4.3 mmol, 1 eq) was dissolved in 15 ml of CH2 Cl2 under nitrogen atmosphere in a 3-necked 100 ml round bottom flask. At room temperature, 2 ml of triethylamine (14.4 mmol, 3.3 eq) was added to the solution and stirred for 30 minutes. N-methyl-N-phenylcarbamoyl chloride (1.6 g, 9.4 mmol, 2.2 eq) was dissolved in 6 ml CH2 Cl2 and added to the reaction mixture dropwise via an addition funnel. The reaction mixture was stirred under N2 for three days before reaching reaction completion. 50 ml of 2N NaOH were added, and the phases were separated. The CH2 Cl2 layer was saved, and the aqueous phase was extracted with 50 ml of CH2 Cl2. The CH2 Cl2 phases were combined and dried over MgSO4 before being concentrated down to afford a gummy pink material. Purification via flash chromatography (silica gel, 95.5 EtOAc/Et3 N, v/v) afforded a yellow material which was then crystallized from CH3 CN to obtain white starlike crystals (1.27 g, 65% yield). Characterization: mp. 119-120 C. High resolution mass spec; calculated molecular mass–459.25217 amu, found–459.2519 amu. 1 H NMR (300 MHz, CDCl3 with TMS); 8.7 delta (d, 1H), 8.0 delta (d,1H), 7.2-7.4 delta (m, 7H) 6.4 delta (d, 1H), 3.8 delta (s,3H), 3.3 delta (s,3H), 3.1 delta (1H), 2.8 delta (q, 1H), 2.6 delta (m, 3H), 1.7 delta (s,2H), 1.3-1.4 delta (m7H), 0.9 delta (t, 3H). 13 C NMR (75 MHz, CDCl3 with TMS): 12.1 delta, 23.9 delta, 25.3 delta, 26.2 delta, 27.3 delta, 37.5 delta, 38.2 delta, 49.8 delta, 50.7 delta, 55.5 delta, 59.7 delta, 75.6 delta, 75.6 delta, 101.8 delta, 119.1 delta, 121.8 delta, 126.3 delta, 126.7 delta, 127.3 delta, 129.1 delta, 131.7, delta143.1 delta, 144.7 delta, 144.9 delta, 147.5 delta, 152.1 delta, 154.8 delta, 157.7 delta.

1435-55-8 Hydroquinidine 16401293, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Massachusetts Institute of Technology; US5227543; (1993); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

0.34 mmol dichloro bridged intermediate and 1.0 g4,7-diphenyl-1,10-phenanthroline was dissolved in 40 mL of ethylene glycol.The reaction system is protected with nitrogen.Stirred at 130 C for 15 hours.After cooling to room temperature, the reaction solution was poured into a 100 mL flask.A saturated NH4PF6 aqueous solution was added thereto with stirring.A large amount of solids precipitated,filter,Wash with a small amount of deionized water,70 C vacuum drying for 5 hours,The crude product is chromatographed on a chromatographic column.a dark brown solidYield 50%.

As the paragraph descriping shows that 1662-01-7 is playing an increasingly important role.

Reference£º
Patent; Tsinghua University; Qiao Juan; Xin Lijun; (29 pag.)CN104804045; (2018); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

1.43 parts by mass of 4-fluoroanisole sulfide, 1.95 parts by mass of silver tetrafluoroborate, and 1-chloromethylnaphthalene 1.77 parts by massAnd 10.0 parts by mass of acetone were uniformly mixed and reacted at 25 C for 24 hours. After removal of silver chloride,The reaction solution was transferred to a rotary evaporator, and the solvent was distilled off, and 10.0 parts by mass of acetone, 10.0 parts of hexane,By mass. 3.33 parts by mass of the obtained precipitate, 1.56 parts by mass of lithium trifluoromethanesulfonate,And 10 parts by mass of acetone were mixed and reacted at 25C for 24 hours. To the reaction solution, 10.0 g of distilled water was addedLt; / RTI & gt; The solvent was removed from the organic layer under reduced pressure, whereby 3.24 parts by mass of the compound 9 was obtained.The mass ratio of the compound B to the total mass of the compound B and the compound A was 0.965. Compared to 4-The yield of fluoroanisole sulfide was 75%. The mass of compound B was 3.13 g and the mass of compound A was 0.11 g.

As the paragraph descriping shows that 33454-82-9 is playing an increasingly important role.

Reference£º
Patent; Asahi Kasei Electronic Materials Co., Ltd.; Zhi, Cunzhong; Shang, Cunzhimi; Da, Guzhang; Dao, Tianren; (89 pag.)CN105579436; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

General procedure: Preparation of four different solutions of tetradecavanadates, VxOyALz (A = Cl- or CH3CO2-, L = (C2H5)4N+ or (C4H9)4N+), was carried out according to a modified literature procedure [31]. All chemicals were purchased from Sigma-Aldrich and used as received. Briefly, 1.5 mmol of vanadyl acetylacetonate [VO(acac)2] and 0.6 mmol of either tetraethylammonium chloride [(C2H5)4NCl], tetrabutylammonium chloride [(C4H9)4NCl], tetraethylammonium acetate [(C2H5)4N(CH3CO2)] or tetrabutylammonium acetate [(C4H9)4N(CH3CO2)] were dissolved in 50 mL of acetonitrile. 0.8 mmol of triethyl amine was then added to the initial mixtures while stirring constantly at room temperature. Following 6 h of reaction, an Oakton 10 series pH meter (calibrated using buffers of pH 4, 7 and 10 at room temperature) was used to determine the pH of the resulting brown-colored solutions. The product mixtures were de-solvated under reduced pressure using a VWR1400E vacuum oven. Recrystallization was carried out in approximately 3 mL of N,N-dimethylformamide (N,N-DMF) by heating the solution to the boiling temperature (153 C) for 10 min. Any remaining N,N-DMF was then evaporated in vacuum to obtain pure dry crystals of polyoxovanadates. A small quantity of crystals was dissolved in acetonitrile to prepare concentrated stock solutions. These stock solutions were diluted further by factors of ten or one hundred in acetonitrile prior to analysis by ESI-MS.

As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

Reference£º
Article; Johnson, Grant E.; Al Hasan, Naila M.; Laskin, Julia; International Journal of Mass Spectrometry; vol. 354-355; (2013); p. 333 – 341;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3030-47-5, N1-(2-(Dimethylamino)ethyl)-N1,N2,N2-trimethylethane-1,2-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of N,N,N?,N?-tetramethylethylene diamine or N,N,N?,N”,N”-pentamethyldiethylene triamine (1 mol) and 1, 3-propanesultone (2.1 mol) in CH3CN was stirred at room temperature for 48 h. On completion,the formed white crystal were filtered and washed with diethylether (3 ¡Á 20 mL), then dried under vacuum at 70 C for 8 h, L1 and L2 were obtained with yields of 95% and 97%, respectively.

3030-47-5 N1-(2-(Dimethylamino)ethyl)-N1,N2,N2-trimethylethane-1,2-diamine 18196, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Li, Xinzhong; Cao, Rong; Lin, Qi; Catalysis Communications; vol. 63; (2015); p. 79 – 83;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The product of Part 17B (131 mg, 0.250 mmol) was dissolved in 2:1 MeCN/H2O (5.00 mL) and successively treated with 14.2 mg TPPTS (25.0 mumol; 10 mol %), Et2NH (129 muL, 1.25 mmol) and 2.8 mg Pd(OAc)2 (12.5 mumol; 5 mol %) at 22 C. Complete deprotection was observed within 0.25 h. The resulting amber solution was then lyophilized to remove all volatile components. The solids thus obtained were redissolved in DMF and successively treated with HOBt (45.9 mg, 0.300 mmol), 2-(1,4,7,10-tetraaza-4,7,10-tris{[(tert-butyl)oxycarbonyl]methyl}-cyclododecyl)acetic acid (172 mg, 0.300 mmol), i-Pr2NEt (105 muL, 0.600 mmol) and HBTU (114 mg, 0.300 mmol) at 22 C. After 0.25 h, complete acylation was observed; only trace amounts of regioisomeric and dimeric products formed. The resulting solution was partitioned between EtOAc and H2O (50 mL each) with transfer to a separatory funnel. The layers separated and the aqueous layer washed with EtOAc (2¡Á50 mL). The EtOAc solution was further washed with 0.1 M NaOH (3¡Á50 mL) and saturated aqueous NaCl (3¡Á50 mL each), then dried over MgSO4, filtered and concentrated in vacuo to a pale yellow oil that was used without further purification in the subsequent deprotection step. The protected conjugate (0.250 mmol theoretical) was dissolved in dioxane (2.50 mL) then successively treated with H2O (23 muL) and HCl (10.0 mmol; 2.50 mL of a 4 M solution in dioxane) at 22 C. The resulting pale yellow solution was stirred 17 h, during which time a heavy white precipitate formed. Upon complete deprotection, the volatiles were removed under a stream of N2 and the white solid residue redissolved in H2O containing 0.1% TFA (8.00 mL) then partially purified by HPLC on a Phenomenex Luna C18 column (21.2¡Á250 mm) using a 2%/min gradient from 0-60% MeCN containing 0.1% TFA and 10% H2O at 20 mL/min. The main product peak eluting at 21 min was collected and lyophilized to a white powder. Final purification was performed using the identical column and method. The main product peak was collected and lyophilized to a white powder (0.110 g, 97.3 mumol; 38.9%).

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; Lantheus Medical Imaging, Inc.; Cesati, Richard R.; Harris, Thomas D.; Robinson, Simon P.; Looby, Richard J.; Cheesman, Edward H.; Yalamanchili, Padmaja; Casebier, David S.; (86 pag.)US9266846; (2016); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI